Symbiotec Pharmalab IPO witnessed a healthy response from investors, with the overall issue subscribed 1.85 times of the 1.31 crore shares on offer.
The issue is currently commanding a grey market premium (GMP) of around 34%, pointing to expectations of a potentially strong listing gain.